Volume 4, Issue 2
Article

Comparative analysis of two rates

Olli Miettinen

Departments of Epidemiology and Biostatistics, Harvard School of Public Health, 677 Huntington Avenue, Boston, Massachusetts 02115, U.S.A.

Search for more papers by this author
Markku Nurminen

Department of Epidemiology and Biostatistics, Institute of Occupational Health, Haartmaninkatu 1, 00290 Helsinki, Finland

Search for more papers by this author
First published: April/June 1985
Citations: 626

Adapted from a lecture before the International Conference on Medical Statistics, Basle, Switzerland, September 8, 1983.

Abstract

In this paper, we examine comparative analysis of rates with a view to each of the usual comparative parameters‐rate difference (RD), rate ratio (RR) and odds ratio (OR)‐and with particular reference to first principles. For RD and RR we show the prevailing statistical practices to be rather poor. We stress the need for restricted estimation of variance in the chi‐square function underlying interval estimation (and also point estimation and hypothesis testing). For RR analysis we propose a chi‐square formulation analogous to that for RD and, thus, one which obviates the present practice of log transformation and its associated use of Taylor series approximation of the variance. As for OR analysis, we emphasize that the chi‐square function, introduced by Cornfield for unstratified data, and extended by Gart to the case of stratified analysis, is based on the efficient score and thus embodies its optimality properties. We provide simulation results to evince the better performance of the proposed (parameter‐constrained) procedures over the traditional ones.

Number of times cited according to CrossRef: 626

  • A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants, Pediatric Infectious Disease Journal, 10.1097/INF.0000000000002765, 39, 8, (763-770), (2020).
  • Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus, Obesity, 10.1002/oby.22748, 28, 4, (724-732), (2020).
  • Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532), Annals of Oncology, 10.1016/j.annonc.2020.04.479, (2020).
  • A phase 3 study evaluating the safety and efficacy of a pediatric dose of mometasone furoate with and without formoterol for persistent asthma, Pediatric Pulmonology, 10.1002/ppul.24667, 55, 4, (882-889), (2020).
  • Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer, Open Forum Infectious Diseases, 10.1093/ofid/ofaa038, 7, 2, (2020).
  • Pembrolizumab for Early Triple-Negative Breast Cancer, New England Journal of Medicine, 10.1056/NEJMoa1910549, 382, 9, (810-821), (2020).
  • Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.02203-19, 64, 5, (2020).
  • Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection, Open Forum Infectious Diseases, 10.1093/ofid/ofaa157, 7, 6, (2020).
  • Optimizing Duration of Empiric Management of Suspected Central Line-Associated Bloodstream Infections (CLABSIs) in Pediatric Intestinal Failure Patients, The Journal of Pediatrics, 10.1016/j.jpeds.2020.07.044, (2020).
  • Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials, Open Forum Infectious Diseases, 10.1093/ofid/ofaa248, 7, 7, (2020).
  • Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia, Medicine, 10.1097/MD.0000000000021223, 99, 29, (e21223), (2020).
  • Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants, Papillomavirus Research, 10.1016/j.pvr.2020.100205, (100205), (2020).
  • Revisit of test‐then‐pool methods and some practical considerations, Pharmaceutical Statistics, 10.1002/pst.2009, 19, 5, (498-517), (2020).
  • Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type, BMC Cancer, 10.1186/s12885-020-07259-5, 20, 1, (2020).
  • Score confidence intervals and sample sizes for stratified comparisons of binomial proportions, Statistics in Medicine, 10.1002/sim.8674, 39, 24, (3427-3457), (2020).
  • Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis, Multiple Sclerosis and Related Disorders, 10.1016/j.msard.2020.102572, (102572), (2020).
  • Association of Inosine Triphosphatase 94C>A and Thiopurine S-Methyltransferase Deficiency with Adverse Events and Study Drop-Outs under Azathioprine Therapy in a Prospective Crohn Disease Study, Clinical Chemistry, 10.1373/clinchem.2005.057158, 51, 12, (2282-2288), (2020).
  • A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study), Clinical Infectious Diseases, 10.1093/cid/ciaa803, (2020).
  • Transition of care of stable ischaemic heart disease patients from tertiary to primary care with telemedicine support: Randomized noninferiority clinical trial, Journal of Telemedicine and Telecare, 10.1177/1357633X20906648, (1357633X2090664), (2020).
  • KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC, Future Oncology, 10.2217/fon-2019-0817, (2020).
  • The Burden of Comorbidity Between Bipolar Spectrum and Obsessive-Compulsive Disorder in an Italian Community Survey, Frontiers in Psychiatry, 10.3389/fpsyt.2020.00188, 11, (2020).
  • Confidence intervals for the difference between two relative risks, Statistical Methods in Medical Research, 10.1177/0962280220915737, (096228022091573), (2020).
  • One-tailed asymptotic inferences for the relative risk: A comparison of 63 inference methods, Communications in Statistics - Theory and Methods, 10.1080/03610926.2020.1760299, (1-19), (2020).
  • Two-tailed asymptotic inferences for the odds ratio in cross-sectional studies: evaluation of fifteen old and new methods of inference, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2020.1757691, (1-16), (2020).
  • Noninferiority Clinical Trials With Binary Outcome: Statistical Methods Used in Practice, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1796780, (1-7), (2020).
  • A Simple Mantel–Haenszel Type Test for Noninferiority, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1736140, (1-6), (2020).
  • Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials, European Journal of Clinical Microbiology & Infectious Diseases, 10.1007/s10096-020-03935-3, (2020).
  • Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials, Diabetes Therapy, 10.1007/s13300-020-00803-3, (2020).
  • Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients, International Journal of Hematology, 10.1007/s12185-020-02953-3, (2020).
  • Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes, Clinical Infectious Diseases, 10.1093/cid/ciaa1035, (2020).
  • Immunogenicity of pentavalent rotavirus vaccine in Chinese infants, Vaccine, 10.1016/j.vaccine.2019.02.018, (2019).
  • Hysterectomy and opportunistic salpingectomy (HOPPSA): study protocol for a register-based randomized controlled trial, Trials, 10.1186/s13063-018-3083-8, 20, 1, (2019).
  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial, The Lancet, 10.1016/S0140-6736(18)32409-7, (2019).
  • A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients, Kidney International, 10.1016/j.kint.2018.11.025, (2019).
  • Ceftaroline Fosamil Therapy in Patients With Acute Bacterial Skin and Skin Structure Infections With Systemic Inflammatory Signs: A Retrospective Dose Comparison Across Three Pivotal Trials, International Journal of Antimicrobial Agents, 10.1016/j.ijantimicag.2019.01.016, (2019).
  • Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials, Cardiovascular Diabetology, 10.1186/s12933-019-0856-7, 18, 1, (2019).
  • Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial, The Lancet Infectious Diseases, 10.1016/S1473-3099(19)30116-1, (2019).
  • Omadacycline for Acute Bacterial Skin and Skin-Structure Infections, New England Journal of Medicine, 10.1056/NEJMoa1800170, 380, 6, (528-538), (2019).
  • Omadacycline for Community-Acquired Bacterial Pneumonia, New England Journal of Medicine, 10.1056/NEJMoa1800201, 380, 6, (517-527), (2019).
  • Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial, The Lancet Haematology, 10.1016/S2352-3026(19)30109-7, (2019).
  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study, The Lancet Oncology, 10.1016/S1470-2045(19)30388-2, (2019).
  • A Multicenter Trial of Vena Cava Filters in Severely Injured Patients, New England Journal of Medicine, 10.1056/NEJMoa1806515, 381, 4, (328-337), (2019).
  • Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.02252-18, 63, 7, (2019).
  • Bridging blinded and unblinded analysis for ongoing safety monitoring and evaluation, Contemporary Clinical Trials, 10.1016/j.cct.2019.06.022, 83, (81-87), (2019).
  • Omadacycline for Acute Bacterial Skin and Skin Structure Infections, Clinical Infectious Diseases, 10.1093/cid/ciz396, 69, Supplement_1, (S23-S32), (2019).
  • Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial, The Lancet, 10.1016/S0140-6736(19)31773-8, (2019).
  • Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial, Open Forum Infectious Diseases, 10.1093/ofid/ofz373, 6, 10, (2019).
  • Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial, Diabetes, Obesity and Metabolism, 10.1111/dom.13631, 21, 4, (1027-1036), (2019).
  • Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia, Diabetes, Obesity and Metabolism, 10.1111/dom.13681, 21, 6, (1474-1482), (2019).
  • Controlling false discovery proportion in identification of drug‐related adverse events from multiple system organ classes, Statistics in Medicine, 10.1002/sim.8304, 38, 22, (4378-4389), (2019).
  • Efficient methods for signal detection from correlated adverse events in clinical trials, Biometrics, 10.1111/biom.13031, 75, 3, (1000-1008), (2019).
  • Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II, Open Forum Infectious Diseases, 10.1093/ofid/ofz293, 6, 8, (2019).
  • Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial, The Lancet Infectious Diseases, 10.1016/S1473-3099(19)30275-0, (2019).
  • Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis, Journal of Thrombosis and Haemostasis, 10.1111/jth.14639, 17, 12, (2081-2088), (2019).
  • A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age, Vaccine, 10.1016/j.vaccine.2019.10.058, (2019).
  • Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study, The Lancet Diabetes & Endocrinology, 10.1016/S2213-8587(19)30346-8, (2019).
  • Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial, The Lancet HIV, 10.1016/S2352-3018(19)30336-4, (2019).
  • Tests for noninferiority trials with binomial endpoints: A guide to modern and quasi‐exact methods for biomedical researchers, Pharmaceutical Statistics, 10.1002/pst.1929, 18, 3, (377-387), (2019).
  • 154 compared to 54 mmol per liter of sodium in intravenous maintenance fluid therapy for adult patients undergoing major thoracic surgery (TOPMAST): a single-center randomized controlled double-blind trial, Intensive Care Medicine, 10.1007/s00134-019-05772-1, 45, 10, (1422-1432), (2019).
  • Diagnostic Strategies for Autosomal Dominant Acute Porphyrias: Retrospective Analysis of 467 Unrelated Patients Referred for Mutational Analysis of the HMBS, CPOX, or PPOX Gene, Clinical Chemistry, 10.1373/clinchem.2008.122564, 55, 7, (1406-1414), (2019).
  • Dose–Response and Thresholds in Mutagenicity Studies: A Statistical Testing Approach, Alternatives to Laboratory Animals, 10.1177/026119290303101s07, 31, 1_suppl, (97-103), (2019).
  • A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants, Human Vaccines & Immunotherapeutics, 10.1080/21645515.2019.1568159, (2019).
  • Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies, Diabetes and Vascular Disease Research, 10.1177/1479164119842513, (147916411984251), (2019).
  • Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis, New England Journal of Medicine, 10.1056/NEJMoa1901713, (2019).
  • Megacities, migration and an evolutionary approach to bipolar disorder: a study of Sardinian immigrants in Latin America, Brazilian Journal of Psychiatry, 10.1590/1516-4446-2018-0338, (2019).
  • PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study, BioDrugs, 10.1007/s40259-019-00363-4, (2019).
  • Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis, Clinical Infectious Diseases, 10.1093/cid/ciz423, (2019).
  • A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL), BioDrugs, 10.1007/s40259-019-00398-7, (2019).
  • Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine When Co-Administered with Tetanus-Reduced Diphtheria-Acellular Pertussis and Quadrivalent Meningococcal Conjugate Vaccines in Healthy Adolescents: Results from a Randomized, Observer-Blind, Controlled Trial, Infectious Diseases and Therapy, 10.1007/s40121-019-00258-5, (2019).
  • Effects of between-batch variability on the type I error rate in biosimilar development, Communications in Statistics - Simulation and Computation, 10.1080/03610918.2019.1650182, (1-18), (2019).
  • Low proportions of folic acid deficiency after introduction of mandatory folic acid fortification in remote areas of northern Queensland, Australia: a secondary health data analysis, Biomarkers, 10.1080/1354750X.2019.1652346, (1-8), (2019).
  • Folic acid deficiency declined substantially after introduction of the mandatory fortification programme in Queensland, Australia: a secondary health data analysis, Public Health Nutrition, 10.1017/S1368980019002258, (1-9), (2019).
  • A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age, Journal of Antimicrobial Chemotherapy, 10.1093/jac/dkz398, (2019).
  • Two-tailed asymptotic inferences for the odds ratio in prospective and retrospective studies: evaluation of methods of inference, Journal of Statistical Computation and Simulation, 10.1080/00949655.2019.1673751, (1-19), (2019).
  • On Analysis of Changes in Rates and Averaged Correlated Rates, Statistics in Biopharmaceutical Research, 10.1080/19466315.2018.1555098, (1-29), (2019).
  • Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin, Current Medical Research and Opinion, 10.1080/03007995.2019.1583450, (1-9), (2019).
  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial, Journal of Clinical Oncology, 10.1200/JCO.19.01307, (JCO.19.01307), (2019).
  • Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin, Diabetes, Obesity and Metabolism, 10.1111/dom.13517, 21, 2, (408-411), (2018).
  • Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study, Diabetes, Obesity and Metabolism, 10.1111/dom.13574, 21, 4, (781-790), (2018).
  • Propensity‐score‐based priors for Bayesian augmented control design, Pharmaceutical Statistics, 10.1002/pst.1918, 18, 2, (223-238), (2018).
  • Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults, Vaccine, 10.1016/j.vaccine.2017.12.038, 36, 5, (668-674), (2018).
  • Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine, Vaccine, 10.1016/j.vaccine.2017.08.029, 36, 1, (179-185), (2018).
  • Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study, Diabetes Therapy, 10.1007/s13300-017-0358-0, 9, 1, (253-268), (2018).
  • Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial, British Journal of Anaesthesia, 10.1016/j.bja.2018.05.056, 121, 4, (749-757), (2018).
  • Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers, British Journal of Anaesthesia, 10.1016/j.bja.2018.05.057, 121, 4, (758-767), (2018).
  • Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing, The European Journal of Contraception & Reproductive Health Care, 10.1080/13625187.2018.1506101, 23, 4, (245-254), (2018).
  • Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants, Vaccine, 10.1016/j.vaccine.2018.02.113, (2018).
  • Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age, Vaccine, 10.1016/j.vaccine.2018.03.012, (2018).
  • Randomized, controlled, proof‐of‐concept trial of MK‐7622 in Alzheimer's disease, Alzheimer's & Dementia: Translational Research & Clinical Interventions, 10.1016/j.trci.2018.03.004, 4, 1, (173-181), (2018).
  • One-tailed asymptotic inferences for the difference of proportions: Analysis of 97 methods of inference, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2018.1452028, 28, 6, (1090-1104), (2018).
  • Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial, European Heart Journal, 10.1093/eurheartj/ehx739, 39, 32, (2987-2996), (2018).
  • Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial, The Lancet Infectious Diseases, 10.1016/S1473-3099(17)30747-8, 18, 3, (285-295), (2018).
  • Comparative Test Evaluation: Methods and Challenges, Journal of Gambling Studies, 10.1007/s10899-018-9745-3, 34, 4, (1109-1138), (2018).
  • Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503), The Lancet Respiratory Medicine, 10.1016/S2213-2600(18)30411-9, (2018).
  • Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: An Integrated Analysis, Multiple Sclerosis and Related Disorders, 10.1016/j.msard.2018.11.021, (2018).
  • Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials, Infectious Diseases and Therapy, 10.1007/s40121-018-0211-4, 7, 4, (509-522), (2018).
  • Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study, The Lancet, 10.1016/S0140-6736(18)31999-8, (2018).
  • Evidence for the effectiveness of chlorhexidine bathing and health care-associated infections among adult intensive care patients: a trial sequential meta-analysis, BMC Infectious Diseases, 10.1186/s12879-018-3521-y, 18, 1, (2018).
  • Validation of a New Method to Automatically Select Cases With Intraoperative Red Blood Cell Transfusion for Audit, Anesthesia & Analgesia, 10.1213/ANE.0000000000002502, 126, 5, (1654-1661), (2018).
  • Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects, Journal of Pediatric Surgery, 10.1016/j.jpedsurg.2018.09.006, (2018).
  • See more

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.